Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies.
Noy-Porat T, Edri A, Alcalay R, Makdasi E, Gur D, Aftalion M, Evgy Y, Beth-Din A, Levy Y, Epstein E, Radinsky O, Zauberman A, Lazar S, Yitzhaki S, Marcus H, Porgador A, Rosenfeld R, Mazor O. Noy-Porat T, et al. Among authors: yitzhaki s. Antibodies (Basel). 2021 Nov 8;10(4):45. doi: 10.3390/antib10040045. Antibodies (Basel). 2021. PMID: 34842604 Free PMC article.
Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody.
Rosenfeld R, Noy-Porat T, Mechaly A, Makdasi E, Levy Y, Alcalay R, Falach R, Aftalion M, Epstein E, Gur D, Chitlaru T, Vitner EB, Melamed S, Politi B, Zauberman A, Lazar S, Beth-Din A, Evgy Y, Yitzhaki S, Shapira SC, Israely T, Mazor O. Rosenfeld R, et al. Among authors: yitzhaki s. Nat Commun. 2021 Feb 11;12(1):944. doi: 10.1038/s41467-021-21239-8. Nat Commun. 2021. PMID: 33574228 Free PMC article.
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.
Noy-Porat T, Makdasi E, Alcalay R, Mechaly A, Levy Y, Bercovich-Kinori A, Zauberman A, Tamir H, Yahalom-Ronen Y, Israeli M, Epstein E, Achdout H, Melamed S, Chitlaru T, Weiss S, Peretz E, Rosen O, Paran N, Yitzhaki S, Shapira SC, Israely T, Mazor O, Rosenfeld R. Noy-Porat T, et al. Among authors: yitzhaki s. Nat Commun. 2020 Aug 27;11(1):4303. doi: 10.1038/s41467-020-18159-4. Nat Commun. 2020. PMID: 32855401 Free PMC article.
Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice.
Noy-Porat T, Mechaly A, Levy Y, Makdasi E, Alcalay R, Gur D, Aftalion M, Falach R, Leviatan Ben-Arye S, Lazar S, Zauberman A, Epstein E, Chitlaru T, Weiss S, Achdout H, Edgeworth JD, Kikkeri R, Yu H, Chen X, Yitzhaki S, Shapira SC, Padler-Karavani V, Mazor O, Rosenfeld R. Noy-Porat T, et al. Among authors: yitzhaki s. iScience. 2021 May 21;24(5):102479. doi: 10.1016/j.isci.2021.102479. Epub 2021 Apr 26. iScience. 2021. PMID: 33937725 Free PMC article.
Mice with induced pulmonary morbidities display severe lung inflammation and mortality following exposure to SARS-CoV-2.
Falach R, Bar-On L, Lazar S, Kadar T, Mazor O, Aftalion M, Gur D, Evgy Y, Shifman O, Aminov T, Israeli O, Cohen-Gihon I, Zaide G, Gutman H, Vagima Y, Makdasi E, Stein D, Rosenfeld R, Alcalay R, Zahavy E, Levy H, Glinert I, Ben-Shmuel A, Israely T, Melamed S, Politi B, Achdout H, Yitzhaki S, Kronman C, Sabo T. Falach R, et al. Among authors: yitzhaki s. JCI Insight. 2021 Jun 22;6(12):e145916. doi: 10.1172/jci.insight.145916. JCI Insight. 2021. PMID: 33974566 Free PMC article.
The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.
Makdasi E, Zvi A, Alcalay R, Noy-Porat T, Peretz E, Mechaly A, Levy Y, Epstein E, Chitlaru T, Tennenhouse A, Aftalion M, Gur D, Paran N, Tamir H, Zimhony O, Weiss S, Mandelboim M, Mendelson E, Zuckerman N, Nemet I, Kliker L, Yitzhaki S, Shapira SC, Israely T, Fleishman SJ, Mazor O, Rosenfeld R. Makdasi E, et al. Among authors: yitzhaki s. Cell Rep. 2021 Sep 7;36(10):109679. doi: 10.1016/j.celrep.2021.109679. Epub 2021 Aug 21. Cell Rep. 2021. PMID: 34464610 Free PMC article.
A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
Yahalom-Ronen Y, Tamir H, Melamed S, Politi B, Shifman O, Achdout H, Vitner EB, Israeli O, Milrot E, Stein D, Cohen-Gihon I, Lazar S, Gutman H, Glinert I, Cherry L, Vagima Y, Lazar S, Weiss S, Ben-Shmuel A, Avraham R, Puni R, Lupu E, Bar-David E, Sittner A, Erez N, Zichel R, Mamroud E, Mazor O, Levy H, Laskar O, Yitzhaki S, Shapira SC, Zvi A, Beth-Din A, Paran N, Israely T. Yahalom-Ronen Y, et al. Among authors: yitzhaki s. Nat Commun. 2020 Dec 16;11(1):6402. doi: 10.1038/s41467-020-20228-7. Nat Commun. 2020. PMID: 33328475 Free PMC article.
Monitoring Group Activity of Hamsters and Mice as a Novel Tool to Evaluate COVID-19 Progression, Convalescence, and rVSV-ΔG-Spike Vaccination Efficacy.
Melamed S, Politi B, Grauer E, Achdout H, Aftalion M, Gur D, Tamir H, Yahalom-Ronen Y, Maimon S, Yitzhak E, Weiss S, Rosner A, Erez N, Yitzhaki S, Shapira SC, Paran N, Mamroud E, Vagima Y, Israely T. Melamed S, et al. Among authors: yitzhaki s. Front Bioeng Biotechnol. 2021 Oct 1;9:737627. doi: 10.3389/fbioe.2021.737627. eCollection 2021. Front Bioeng Biotechnol. 2021. PMID: 34660558 Free PMC article.
Preliminary nonclinical safety and immunogenicity of an rVSV-ΔG-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs.
Madar-Balakirski N, Rosner A, Melamed S, Politi B, Steiner M, Tamir H, Yahalom-Ronen Y, Bar-David E, Ben-Shmuel A, Sittner A, Glinert I, Weiss S, Bar-Haim E, Cohen H, Elia U, Achdout H, Erez N, Rotem S, Lazar S, Nyska A, Yitzhaki S, Beth-Din A, Levy H, Paran N, Israely T, Marcus H. Madar-Balakirski N, et al. Among authors: yitzhaki s. Arch Toxicol. 2022 Mar;96(3):859-875. doi: 10.1007/s00204-021-03214-w. Epub 2022 Jan 15. Arch Toxicol. 2022. PMID: 35032184 Free PMC article.
54 results